BiotechTube

TD-1792 + Vancomycin

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Staphylococcal Skin Infection

Conditions

Staphylococcal Skin Infection

Trial Timeline

Dec 1, 2006 → May 1, 2007

NCT ID
NCT00442832

About TD-1792 + Vancomycin

TD-1792 + Vancomycin is a phase 2 stage product being developed by Theravance Biopharma for Staphylococcal Skin Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00442832. Target conditions include Staphylococcal Skin Infection.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00442832Phase 2Completed

Competing Products

20 competing products in Staphylococcal Skin Infection

See all competitors
ProductCompanyStageHype Score
CeftobiproleJohnson & JohnsonPhase 1
33
CeftobiproleJohnson & JohnsonPhase 1
33
Daptomycin + VancomycinMerckApproved
85
Daptomycin 4 mg/kg + Comparator: vancomycin + Daptomycin 6 mg/kgMerckPhase 3
77
V710 + PlaceboMerckPhase 1
33
V710 + Comparator: PlaceboMerckPhase 1
33
V710 (30 µg) with MAA + V710 (30 µg) without MAAMerckPhase 1
33
Daptomycin + VancomycinMerckApproved
85
DaptomycinNovartisApproved
85
SA4Ag vaccinePfizerPhase 1
32
Staphylococcus aureus 4-Antigen (SA4Ag) VaccinePfizerPhase 2
51
linezolid (Zyvox)PfizerPre-clinical
22
Staphylococcus aureus 4-antigen vaccine + PlaceboPfizerPhase 2
51
TigecyclinePfizerApproved
84
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + PlaceboPfizerPhase 1
32
SA4Ag vaccine low dose + SA4Ag vaccine mid dose + SA4Ag vaccine high dose + SA3Ag vaccine + PlaceboPfizerPhase 1
32
NDV-3 vaccine with alum IM + NDV-3 vaccine without alum IM + Placebo with alum IM + NDV-3 vaccine without alum IDUnited TherapeuticsPhase 1
30
NDV-3 investigational vaccineUnited TherapeuticsPhase 1
30
CeftobiproleBasilea PharmaceuticaPhase 1
28
human lactoferrin peptide 1-11AM-PharmaPhase 1/2
33

Other Products from Theravance Biopharma

TelavancinApproved
80
umeclidinium 62.5 µg and vilanterol 25 µg + Revefenacin 175 µg, Formoterol 20 µg + Placebo ( Revefenacin and Formoterol ) + Placebo DPIApproved
80
Ampreloxetine + PlaceboPhase 3
72
ampreloxetine + PlaceboPhase 3
72
ampreloxetine + PlaceboPhase 3
72